GSK plc has officially commenced a tender offer to acquire all issued and outstanding shares of Class A and Class B common stock of Nuvalent, Inc. for $124.00 per share in cash. The transaction is being executed through a direct wholly-owned subsidiary of GlaxoSmithKline LLC.
Nuvalent is a clinical-stage biopharmaceutical company specializing in precisely targeted small molecule therapies designed to overcome the limitations and resistance of existing cancer treatments. The acquisition will integrate Nuvalent’s robust pipeline including investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer into GSK’s global oncology portfolio.
Nuvalent’s Board of Directors has filed a Schedule 14D-9 with the SEC, recommending that stockholders accept the offer and tender their shares. The tender offer and withdrawal rights are scheduled to expire at one minute following 11:59 p.m. Eastern Time on July 14, 2026, unless extended. The closing is subject to customary conditions, including the tender of at least a majority of outstanding Class A shares and regulatory approvals.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
